rivastigmine hydrogen tartrate
PolandDrugs containing this active substance
-
The medicine is used in adult patients with mild to moderately severe Alzheimer's-type dementia and in individuals with dementia related to Parkinson's disease.
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 2.4 mg ATC: N06DA03
Manufacturer: Bausch Health Poland Sp. z o.o.
-
The medicine is used in adult patients to relieve the symptoms of mild to moderately severe Alzheimer's-type dementia and dementia associated with Parkinson's disease.
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 4.8 mg ATC: N06DA03
Manufacturer: Bausch Health Poland Sp. z o.o.
-
The medicine is used in adult patients to relieve the symptoms of mild to moderate Alzheimer's-type dementia and dementia associated with Parkinson's disease.
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 7.2 mg ATC: N06DA03
Manufacturer: Bausch Health Poland Sp. z o.o.
-
The medicine is used in adult patients for the treatment of mild to moderately severe Alzheimer's-type dementia and in the treatment of dementia in people with Parkinson's disease.
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 9.6 mg ATC: N06DA03
Manufacturer: Bausch Health Poland Sp. z o.o.
-
The medicinal product is used in adult patients for the treatment of mild to moderately severe Alzheimer's type dementia and for the treatment of dementia associated with Parkinson's disease.
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 2.4 mg ATC: N06DA03
Manufacturer: Genepharm S.A. neuraxpharm Arzneimittel GmbH
-
The medicine is used in adult patients to alleviate the symptoms of mild to moderately severe Alzheimer's-type dementia and dementia associated with Parkinson's disease.
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 4.8 mg ATC: N06DA03
Manufacturer: Genepharm S.A. neuraxpharm Arzneimittel GmbH
-
The medicine is used in adult patients to relieve the symptoms of mild to moderately severe Alzheimer's-type dementia and dementia associated with Parkinson's disease.
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 7.2 mg ATC: N06DA03
Manufacturer: Genepharm S.A. neuraxpharm Arzneimittel GmbH
-
The medicinal product is used in adult patients to alleviate the symptoms of mild to moderately severe Alzheimer's-type dementia and dementia associated with Parkinson's disease.
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 9.6 mg ATC: N06DA03
Manufacturer: Genepharm S.A. neuraxpharm Arzneimittel GmbH
-
The medicine is used in adult patients to alleviate the symptoms of mild to moderately severe Alzheimer's-type dementia and dementia associated with Parkinson's disease.
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 2.4 mg ATC: N06DA03
Manufacturer: Orion Corporation Orion Pharma
-
The medicinal product is used in adult patients for the treatment of mild to moderately severe Alzheimer's type dementia and for the treatment of dementia in people with Parkinson's disease.
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 4.8 mg ATC: N06DA03
Manufacturer: Orion Corporation Orion Pharma
-
The medicine is used in adult patients to relieve the symptoms of mild to moderately severe Alzheimer's-type dementia and dementia associated with Parkinson's disease.
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 7.2 mg ATC: N06DA03
Manufacturer: Orion Corporation Orion Pharma
-
The medicinal product is intended for adult patients with mild to moderately severe Alzheimer's-type dementia and for individuals with dementia caused by Parkinson's disease.
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 9.6 mg ATC: N06DA03
Manufacturer: Orion Corporation Orion Pharma